Positioning no disclosures inside 60 days, left as found
Options put/call open interest 67.75, read 2026-11-01
Ethical does not pass the values gate
Price52.70 USD
Fair value38.08
Ethical score70.0/100
Value readOvervaluedas of 7 Nov 2026
Our investment reviews on this name
2026-11-01Read Accumulation52.76-0.1% to today Markdown gives way to Accumulation
2026-10-16Read Markdown52.39+0.6% to today Accumulation gives way to Markdown
2026-10-02Read Accumulation52.41+0.6% to today ✓Markup gives way to Accumulation after a 52% rise in 4 weeks
2026-09-01Read Markup34.52+52.7% to today ✓Accumulation gives way to Markup first Markup read since July
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
MarineMax, Inc. holds its Accumulation at $52.70. Consolidating, no directional conviction, held for 38 days.
As held on the ledger · 2026-11-07
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 38 days
Price at the screen
$52.70
Valuation
N/A trailing · 20.48 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.73
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
50.43%
Below 33%
Interest-bearing debt is 50.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.21%
Below 49%
Money owed to the company is 10.2% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
MarineMax,'s business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HZO's ethical verdict changes
Today HZO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 7 Nov 2026: it trades above our $38.08 fair value estimate.
Fair value range in USD, drawn from the 2026-11-07 screen. The gold marker is the market price at the same screen. The price runs 38.4% above the base estimate.
Where our models see it going: fair-value estimate $38.08, with a range of $31.50 to $43.79, dated to the 2026-11-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 20.5x forward earnings, the price already runs ahead of the business. It trades 38% above our $38.08 fair value, so you would be buying at a premium, not a discount.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HZO trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$52.65-0.1%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$52.70-0.1%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$52.76+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$52.45+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$52.45+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$52.45+0.1%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 51% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$52.39+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35.
2026-10-16Markdown · changed$52.390.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 51.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $35. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.